Evidence map›Paper›PMID 38338672›Full record

ArticleInternational journal of molecular sciences2024

In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.

Genqiao Jiang, Brigitte Neuber, Angela Hückelhoven-Krauss, Uta E Höpken, Yuntian Ding, David Sedloev, Lei Wang, Avinoam Reichman, Franziska Eberhardt, Martin Wermke and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Genqiao JiangDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Brigitte NeuberDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Angela Hückelhoven-KraussDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Uta E HöpkenDepartment of Translational Tumor Immunology, Max-Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, Germany.
Yuntian DingDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
David SedloevDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Lei WangDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Avinoam ReichmanDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Franziska EberhardtDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Martin WermkeEarly Clinical Trial Unit (ECTU), Medical Clinic and Poliklinik I, Carl Gustav Carus University, 01307 Dresden, Germany.
Armin RehmDepartment of Translational Tumor Immunology, Max-Delbrück Center for Molecular Medicine (MDC), 13125 Berlin, Germany.
Carsten Müller-TidowDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Anita SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.
Michael SchmittDepartment of Internal Medicine V, University Clinic Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-1579-1509
Heidelberg University · DEMax Delbrück Center · DEUniversity Hospital Carl Gustav Carus · DE

Funding

German Cancer Research Center NCT05836896
6 · The paper itself

Abstract

The search for target antigens for CAR-T cell therapy against multiple myeloma defined the B-cell maturation antigen (BCMA) as an interesting candidate. Several studies with BCMA-directed CAR-T cell therapy showed promising results. Second-generation point-of-care BCMA.CAR-T cells were manufactured to be of a GMP (good manufacturing practice) standard using the CliniMACS Prodigy

Indexed as

Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenCryopreservationCytokinesHumansImmunotherapy, AdoptivePoint-of-Care SystemsT-LymphocytesB-Cell Maturation AntigenCytokinesReceptors, Chimeric AntigenB-cell maturation antigen (BCMA)CAR-T cellsmultiple myelomastability and function of CAR-T cellstimepoint

Identifiers

PMID38338672
PMCPMC10855166
OpenAlexW4391174561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.